Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
Clinical trial NCT01180959 · COMPLETED
Trial details
- NCT number
- NCT01180959
- Sponsor
- M.D. Anderson Cancer Center
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-04-14
- Primary completion
- 2021-05-19
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.